San Francisco startup Structure Therapeutics can be focusing on an oral, once-daily GLP-1 drug named GSBR-1290—the drug surpassed Wall Avenue’s expectations in June each time a mid-phase examine confirmed normal weight loss of around 6% and it options to get started on Yet another mid-stage trial toward the top of the yr—that founder and CEO